Analysts who follow Freeline Therapeutics Holdings PLC (FRLN) on average expect it to climb 566.67% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns the stock an Analyst Ranking of 59, which means it ranks higher than 59 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating FRLN a Strong Buy today. Find out what this means to you and get the rest of the rankings on FRLN!